IDEAS home Printed from https://ideas.repec.org/a/plo/pmed00/1001201.html
   My bibliography  Save this article

The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience

Author

Listed:
  • Peter Doshi
  • Tom Jefferson
  • Chris Del Mar

Abstract

Peter Doshi and colleagues describe their experience trying and failing to access clinical study reports from the manufacturer of Tamiflu and challenge industry to defend their current position of RCT data secrecy.

Suggested Citation

  • Peter Doshi & Tom Jefferson & Chris Del Mar, 2012. "The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience," PLOS Medicine, Public Library of Science, vol. 9(4), pages 1-6, April.
    • Handle: RePEc:plo:pmed00:1001201
    DOI: 10.1371/journal.pmed.1001201
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001201
    Download Restriction: no
    File URL: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1001201&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pmed.1001201?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Frederic Bouder & Dominic Way & Ragnar Löfstedt & Darrick Evensen, 2015. "Transparency in Europe: A Quantitative Study," Risk Analysis, John Wiley & Sons, vol. 35(7), pages 1210-1229, July.
    2. Katja Voit & Cristian Timmermann & Florian Steger, 2021. "Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical Analysis," IJERPH, MDPI, vol. 18(11), pages 1-16, May.
    3. Francetic, Igor, 2021. "Bad law or implementation flaws? Lessons from the implementation of the new law on epidemics during the response to the first wave of COVID-19 in Switzerland," Health Policy, Elsevier, vol. 125(10), pages 1285-1290.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:1001201. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.